Company Filing History:
Years Active: 2017-2019
Title: Murli Krishna: Innovator in Antibody Development
Introduction
Murli Krishna is a notable inventor based in Yardley, PA (US). He has made significant contributions to the field of immunology, particularly in the development of antibodies that interact with polyethylene glycol (PEG). With a total of 2 patents, his work is paving the way for advancements in therapeutic applications.
Latest Patents
Murli Krishna's latest patents focus on methods of using human Fc-bearing IGG antibodies to PEG. PEG is commonly conjugated with therapeutic proteins to enhance their pharmacokinetic properties. However, it can be immunogenic, leading to the presence of pre-existing anti-PEG antibodies in humans. His patents provide polyclonal and monoclonal antibodies reactive to PEG for use in immunogenicity assay development. These antibodies exhibit preferential binding based on the size of PEG, with molecular weights ranging from 350 daltons to 40 kD. The engineered anti-PEG antibodies comprise human Fc regions, enabling non-bridging immunoassay formats.
Career Highlights
Murli Krishna is currently employed at Bristol-Myers Squibb Company, where he continues to innovate in the field of antibody development. His work is crucial in addressing the challenges posed by PEG in therapeutic applications.
Collaborations
Some of his notable coworkers include Alexander T Kozhich and Martin J Corbett. Their collaborative efforts contribute to the advancement of research and development in the field.
Conclusion
Murli Krishna's contributions to the field of immunology through his patents and work at Bristol-Myers Squibb Company highlight his role as an influential inventor. His innovative approaches to antibody development are set to make a significant impact in therapeutic applications.